10-Q: VolitionRx Secures $6.25 Million Funding via Convertible Note and Warrant Agreement with Lind Global Asset Management

VolitionRx enters into a securities purchase agreement with Lind Global Asset Management for $6.25 million in funding, issuing a convertible note and common stock purchase warrant.

Summary

• VolitionRx Limited has entered into a securities purchase agreement with Lind Global Asset Management XII LLC to secure $6.25 million in funding.
• The agreement involves the issuance of a Senior Secured Convertible Promissory Note for $7.5 million and a Common Stock Purchase Warrant for 13,020,834 shares at $0.672 per share.
• The company will pay a commitment fee of $218,750 to Lind, deducted from the initial funding.
• The note does not accrue interest and will be repaid in 18 monthly installments of $416,666 starting six months from the issuance date.
• Lind has the option to increase up to two monthly payments to $1,000,000.
• Repayments can be made in cash (at 1.05 times the payment amount), shares, or a combination.
• The conversion price for the note is $0.72 per share, subject to adjustment.
• Lind can convert the note at any time, with the converted amount applied to upcoming note payments.
• The company can prepay the note in whole after 30 days, subject to Lind's option to convert up to one-third of the principal at a specified price.
• The issuance of shares is subject to beneficial ownership limitations and potential stockholder approval.

Sentiment

Score: 6

Explanation: The announcement is neutral. While securing funding is positive, the terms of the agreement, including the secured nature of the debt and the potential for dilution, introduce risks.

Positives

• The funding provides VolitionRx with additional capital for working capital purposes.
• The convertible note structure allows for potential debt reduction through conversion to equity.
• The agreement includes flexibility in repayment options, allowing the company to manage cash flow.
• The company retains the right to prepay the note, providing potential for future financial optimization.

Negatives

• The agreement includes a commitment fee of $218,750, reducing the net funding received.
• The note does not accrue interest, but cash repayments are subject to a 1.05 multiplier.
• The issuance of shares is subject to beneficial ownership limitations and potential stockholder approval, which could restrict conversion options.
• The company is subject to certain negative covenants, including restrictions on distributions, stock repurchases, borrowing, sale of assets, loans and exchange offers.

Risks

• The company's obligations under the note are secured by a first-priority security interest in all of its assets.
• The company's subsidiaries have guaranteed all of the obligations of the company.
• The agreement includes events of default that could trigger acceleration of the debt.
• The company is subject to certain negative covenants, including restrictions on distributions, stock repurchases, borrowing, sale of assets, loans and exchange offers.
• The company may be required to utilize a portion of the proceeds from certain specified debt or equity transactions and asset sales to repay the outstanding principal amount due under the Lind Note.

Future Outlook

The funding is intended to provide VolitionRx with additional capital for working capital purposes. The company expects to monetize its IP and technologies through licensing and distribution contracts with companies that have established distribution networks and expertise on a worldwide or regional basis, in both human and animal care across platforms (centralized labs and point-of-care / in-house diagnostics).

Industry Context

This announcement reflects a common financing strategy for biotechnology companies, which often rely on debt and equity financing to fund ongoing research and development activities. The use of convertible notes and warrants is a typical approach to attract investors while providing flexibility for the company.

Comparison to Industry Standards

• Comparable companies in the diagnostics space, such as Exact Sciences and Guardant Health, have also utilized convertible notes and equity offerings to raise capital.
• The terms of the agreement, including the interest rate, conversion price, and warrant coverage, appear to be within the range of similar transactions in the industry.
• The secured nature of the note and the guarantees from subsidiaries provide additional security for the investor, which is a common practice in debt financing for companies with limited revenue.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into equity.
• Employees may benefit from the increased financial stability of the company.
• Customers and suppliers may see continued operations and development of new products.
• Creditors may be impacted by the secured nature of the debt, which could affect their priority in the event of a bankruptcy.

Next Steps

• The company will receive $6.25 million in funding from Lind Global Asset Management XII LLC within ten business days.
• The company will repay the note in 18 monthly installments starting six months from the issuance date.
• The company may seek stockholder approval to issue shares in excess of the NYSE 19.99% Cap.
• The company will file a registration statement covering the resale of the Investor Shares.

Key Dates

Keywords

convertible note, warrant, funding, securities purchase agreement, Lind Global Asset Management, VolitionRx, capital raise, debt financing